EP1516620B1 - Rifampicin for treating angiogenesis - Google Patents
Rifampicin for treating angiogenesis Download PDFInfo
- Publication number
- EP1516620B1 EP1516620B1 EP03733506A EP03733506A EP1516620B1 EP 1516620 B1 EP1516620 B1 EP 1516620B1 EP 03733506 A EP03733506 A EP 03733506A EP 03733506 A EP03733506 A EP 03733506A EP 1516620 B1 EP1516620 B1 EP 1516620B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis
- rifampicin
- rifamycin
- gene
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title claims description 50
- 229960001225 rifampicin Drugs 0.000 title claims description 48
- 230000033115 angiogenesis Effects 0.000 title claims description 44
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000004263 retinal angiogenesis Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 238000007634 remodeling Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 19
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 16
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 13
- 102400001047 Endostatin Human genes 0.000 description 12
- 108010079505 Endostatins Proteins 0.000 description 12
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 229960000885 rifabutin Drugs 0.000 description 10
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 10
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 9
- 229940109171 rifamycin sv Drugs 0.000 description 9
- BBNQHOMJRFAQBN-UPZFVJMDSA-N 3-formylrifamycin sv Chemical compound OC1=C(C(O)=C2C)C3=C(O)C(C=O)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BBNQHOMJRFAQBN-UPZFVJMDSA-N 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 229930189077 Rifamycin Natural products 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 5
- 108010040765 Integrin alphaV Proteins 0.000 description 4
- 108010020950 Integrin beta3 Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 229960003292 rifamycin Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 102400000068 Angiostatin Human genes 0.000 description 3
- 108010079709 Angiostatins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000006170 formylation reaction Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108700024542 myc Genes Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006500 Brucellosis Diseases 0.000 description 2
- 208000007190 Chlamydia Infections Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 2
- RAFHKEAPVIWLJC-OQQFTUDCSA-N Rifamycin O Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC5(OCC(=O)O5)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C RAFHKEAPVIWLJC-OQQFTUDCSA-N 0.000 description 2
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 description 2
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- SQTCRTQCPJICLD-KTQDUKAHSA-N rifamycin B Chemical compound OC1=C(C(O)=C2C)C3=C(OCC(O)=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O SQTCRTQCPJICLD-KTQDUKAHSA-N 0.000 description 2
- SQTCRTQCPJICLD-OQQFTUDCSA-N rifomycin-B Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(OCC(=O)O)c4c3C2=O SQTCRTQCPJICLD-OQQFTUDCSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- RAFHKEAPVIWLJC-TWYIRNIGSA-N z67lem9p1w Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N2)C)OC)C(C(=C3O)C)=C1C1=C3C(=O)C2=C[C@]11OCC(=O)O1 RAFHKEAPVIWLJC-TWYIRNIGSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001468213 Amycolatopsis mediterranei Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 troches Substances 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Definitions
- the present invention relates to an angiogenesis inhibitor rifampicin, and more particularly, to a novel angiogenesis inhibitor rifampicin effective for inhibition of angiogenesis in malignant tumor, diabetic retinopathy, retinal angiogenesis, and angiogenesis accompanying cardiovascular remodeling.
- Angiogenesis is a process in which new blood vessels are generated from existing blood vessels, and it is known that angiogenesis is closely involved in an onset and development of diseases such as malignant (solid) tumor, diabetic retinopathy, or retinal angiogenesis, inflammatory diseases (rheumatism, etc.).
- diseases such as malignant (solid) tumor, diabetic retinopathy, or retinal angiogenesis, inflammatory diseases (rheumatism, etc.).
- solid tumors in order for solid tumors to grow, it is necessary to secure a supply route of nutrition and oxygen and an elimination route of wastes by angiogenesis.
- Angiogenesis plays an important role for tumor metastasis, an issue special concern for cancer treatment, since angiogenesis secures the blood supply.
- diabetic retinopathy angiogenesis itself is a pathological condition, and patients lose their eyesight if left untreated. Therefore, it is considered that inhibition of angiogenesis leads to prevention/treatment of diseases, and preventing/treating agents for angiogenesis are currently explored.
- angiogenesis promotes various pathological conditions mentioned above, inhibition of angiogenesis is expected to be beneficial in prevention/treatment of such conditions.
- studies in search for angiogenesis-inhibiting substances have been performed.
- many angiogenesis-inhibiting substances have been identified, and for some of them, clinical usefulness is now under investigation.
- angiogenesis inhibitors such as endostatin and angiostatin were once known to be the most potent agents for tumor dormancy therapy. They were expected to serve as ideal anticancer drugs with least adverse reactions because their systemic therapy regressed solid tumors in experimental animals remarkably ( Cell, 88, 277-285, 1997 ) without any acquired resistance as experimental tumors do not develop resistance to multiple cycles of therapy unlike conventional anticancer drugs ( Nature, 390, 404-407, 4997 ). However, in clinical practice, synthesis of an effective dosage of these high molecular proteins to elicit antitumor effect is difficult and costly and, consequently, business circles have already abandoned clinical applications of angiostatin, whose molecular weight is about 50000.
- Endostatin with lower molecular weight (about 20000), attracted attention and its clinical applications have started in terminal malignant tumor patients in U.S.A. However, its precise mechanisms of action as well as its receptors had been unknown.
- Endostatin inhibits the proliferation of endothelial cells and induces apoptosis under reduced serum culture condition ( J. Biol. Chem., 274, 11721-11726, 1999 ), but since the effect was limited, and it was difficult to ascribe the potent effect to regress primary and metastatic cancers.
- Tumor cells attain accelerated proliferative characteristics not only by genomic mutation and deregulated gene expression but also by vigorously secreting many growth- and angiogenesis-promoting factors in an autocrine/paracrine fashion; and further, newly generated blood vessels supply abundant blood flow.
- potent intracellular signals specificallyacting on endothelial cells must be induced. These mechanisms have been unknown for long time.
- Rifamycin in the culture liquid is a mixture comprising rifamycins A, B, C, D, E, etc., and rifamycin O is an oxidized type of rifamycin B.
- Rifamycin B and rifamycin O are induced into rifamycin S, and rifamycin S is reduced to rifamycin SV by ascorbic acid.
- 3-formyl rifamycin is made by 3-formylation of rifamycin.
- Rifampicin is induced from a substance made by 3-formylation of rifamycin SV.
- Rifamycin is collectively called as ansamycin antibiotics because it has an aromatic ring system to which an aliphatic bridge called ansa ring is connected.
- rifampicin is an ansamycin antibiotic developed from a collaboration of Ciba-Geigy (Switzerland) and Lepetit (Italy), and is induced from a substance made by 3-formylation of rifamycin SV.
- rifampicin is an ansamycin semisynthetic antibiotic having a structure of 3- ⁇ [(4-methyl-1-piperazinyl)imino]methyl ⁇ rifamycin, and is a substance which has excellent antituberculosis activity and has been used widely as an anti-tuberculous drug.
- Rifampicin has antibacterial activity not only to Gram-positive bacteria but also to Gram-negative bacillus, and has been used for brucellosis, chlamydia infection, and infection of Gram-positive bacteria such as staphylococcus as well as tuberculosis.
- Malkowska-Zwierz et al. discloses that rifampicin inhibits the angiogenic activity of human blood mononuclears (MNC) in a leukocyte induced angiogenesis test but not the angiogenic activity of tumour cells in a tumour induced angiogenesis test ( MALKOWSKA-ZWIERZ ET AL., INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 7, 1995, page 968 ).
- MNC human blood mononuclears
- Rifampicin is synthesized by reacting 3-formyl rifamycin SV with 1-amino-4-methylpiperazine in tetrahydrofran, and many synthetic methods including industrial synthetic methods are disclosed (Japanese Patent Publication Nos. 42-26800 , 47-23303 , 53-39400 , 57-40155 , 62-41671 , 62-41672 , and 62-41673 ).
- the object of the present invention is to provide a novel angiogenesis inhibitor which is safe and highly practical, more particularly, a novel angiogenesis inhibitor which is effective, safe and highly practical for inhibition of angiogenesis in various diseases such as malignant tumor, diabetic retinopathy and retinal angiogenesis.
- rifampicin which has excellent antituberculous and antibacterial activity to both Gram-positive and negative bacteria and widely used to treat brucellosis, chlamydia infection, and staphylococcus infection as well as tuberculosis, has excellent angiogenesis-inhibiting activity. This led to the completion of the present invention. It is furthermore disclosed that ansamycin antibiotics such as rifamycin SV or 3-formyl rifamycin have angiogenesis-inhibiting activity as well.
- ansamycin antibiotics such as rifampicin have excellent angiogenesis-inhibiting activity has its origin in the elucidation of endostatin-induced molecular signals by the present inventors.
- the present inventors have found a molecular mechanism involved in inhibition of angiogenesis by endostatin ( FASEB Journal. 15, 1044-1053, 2001 ).
- Administration of endostatin at concentrations showing tumor regression in experimental animals markedly inhibited various immediately early response genes and apoptosis/cell-cycle/migration-associated genes expressed in cultured vascular endothelial cells under supplementation with serum, growth factors and angiogenesis factors.
- endostatin causes marginal endothelial cell proliferation, but marked inhibition of endothelial cell migration.
- the molecular responses, which are potent and wide spectrum of gene down-regulation by endostatin, are designated as "angiogenesis-inhibiting signals" by a present inventor.
- ansamycin antibiotics such as rifampicin have been found to induce strong angiogenesis-inhibiting activity among many candidate substances. Since ansamycins such as rifampicin have been widely used as antibiotics, their safety is well known and method for producing and administering them have been established. Therefore, it is expected that they can be used as highly practical angiogenesis inhibitors.
- the present invention comprises an angiogenesis inhibitor containing an ansamycin antibiotic or a pharmacologically acceptable derivative thereof as an active ingredient (“1"), the angiogenesis inhibitor according to "1", wherein the ansamycin antibiotic is rifampicin, ("2"), the angiogenesis inhibitor according to "1” or “2", wherein the pharmacologically acceptable derivative is a pharmacologically acceptable salt or a hydrate thereof (“3"), the angiogenesis inhibitor according to any one of “1” to “3”, wherein angiogenesis in malignant tumor is inhibited ("4"), the angiogenesis inhibitor according to anyone of "1” to “3”, wherein angiogenesis in diabetic retinopathy is inhibited ("5"), the angiogenesis inhibitor according to anyone of "1” to “3”, wherein angiogenesis in retinal angiogenesis is inhibited ("6”) , and the angiogenesis inhibitor according to any one of "1” to “3”, wherein angiogenesis accompanying cardiovascular remodeling is inhibited ("8").
- the present invention comprises angiogenesis inhibitors containing the ansamycin antibiotic rifampicin or a pharmacologically acceptable derivative thereof as defined below as an active ingredient.
- the angiogenesis inhibitor can be used for inhibiting angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis and angiogenesis accompanying cardiovascular remodeling , respectively.
- the active ingredients of the present invention comprise ansamycin antibiotics such as rifampicin.
- the active ingredients of the present invention can be appropriately converted into, for example, pharmacologically acceptable derivatives in order to increase water-solubility for the purpose of easier administration (Japanese Patent Publication No. 5-44467 ).
- As one of the pharmacologically acceptable derivatives it is possible to convert the ingredients into the form of pharmacologically acceptable salts or hydrates thereof, which are used in formulation of medicines usually.
- any known producing methods can be used for preparing the active ingredients of the present invention rifampicin.
- angiogenesis inhibitor of the present invention For administration of the angiogenesis inhibitor of the present invention, appropriate administration method such as oral or parenteral administration (intravenous, intramuscular, subcutaneous administration, or instillation) can be used in accordance with subjects of administration.
- oral administration the active ingredients of the present invention can be formulated as a solid or liquid prescribed drug, for instance, in the form of tablets, granules, capsules, powders, troches, solutions, suspensions, or emulsions.
- parenteral administration the active ingredients of the present invention can be prepared as, for example, an injectable prescribed drug by using an appropriate solvent.
- solvent examples include water, aqueous solvents (sodium chloride solution, glucose solution, etc.), water-miscible solvents (ethyl alcohol, polyethylene glycol, propylene glycol, etc.), and nonaqueous solvents (corn oil, cottonseed oil, peanut oil, sesame oil, etc.).
- aqueous solvents sodium chloride solution, glucose solution, etc.
- water-miscible solvents ethyl alcohol, polyethylene glycol, propylene glycol, etc.
- nonaqueous solvents corn oil, cottonseed oil, peanut oil, sesame oil, etc.
- Dosage of the active ingredients of the present invention is appropriately determined according to subjects and forms of administration, however, as an example of dosage unit for oral administration, an amount containing about 50 - 1000 mg of the active ingredients, preferably, about 150 - 500 mg of the active ingredients, is exemplified.
- Rifampicin the active ingredient of the present invention, is a medicine which have been already used for innumerable patients including tuberculosis patients, and its dosage regimen and side effect are well known. Therefore, when using the medicines of the present invention, dosage form and dosage method based on such experiences can be used.
- RNAs were subjected to quantification of mRNA of various genes using LightCycler-based highly sensitive real-time quantitative PCR ( FASEB J., 15, 1044-1053, 2001 ). The results are shown in Fig. 1 .
- A represents the results of quantification of focal adhesion kinase gene
- B represents those of platelet endothelial cell adhesion molecule-1 (PECAM-1) genes
- C represents those of integrin- ⁇ v gene which is an adhesive factor
- D represents those of integrin- ⁇ 3 gene which is another adhesive factor
- E represents those of endothelin-1 gene which is a vasoconstrictive peptide
- F represents those of endothelin receptor subtype B (ET B ) gene
- G represents those of c-myc gene which is an immediate early response gene
- H represents those of Flt gene which is a subtype of vascular endothelial growth factor (VEGF) receptor, respectively.
- VEGF vascular endothelial growth factor
- Example 2 Inhibitory activity of rifampicin against proliferation of vascular endothelial cells
- Example 3 Inhibitory activity of rifampicin against migration of vascular endothelial cells
- Fig. 3 The results are shown in Fig. 3 .
- the advanced distances of vascular endothelial cells were markedly decreased by the addition of 40 ⁇ g/ml of rifampicin.
- rifampicin inhibited chemotactic migration of adult human dermal microvascular endothelial cells.
- Example 5 Experience of use in patients with hepatoma associated with hepatitis C-related liver cirrhosis
- the present inventor specializing in liver diseases administered rifampicin to patients with hepatitis C-related liver cirrhosis associated with lung tuberculosis, and noted a rapid drop in plasma ⁇ -fetoprotein levels.
- the present inventors further noted that hepatoma never recurred during the long term despite the repeated previous episodes of recurrence. Relationship between the changes of plasma ⁇ -fetoprotein levels and rifampicin administration in two patients is shown in Fig. 5 .
- Angiogenesis-inhibiting signals (the changes of gene expression levels) induced by addition of rifampicin, rifamycin SV and 3-formyl rifamycin
- A, B and C represent the quantification results of c-myc gene; D, E and F represent those of integrin- ⁇ v gene; G, H and I represent those of integrin- ⁇ 3 gene.
- A, D and G indicate the changes of mRNA levels after adding rifampicin;
- B, E and H indicate those after adding rifamycin SV;
- C, F and I indicate those after adding 3-formyl rifamycin.
- angiogenesis-inhibiting signals are markedly elicited by rifampicin in human retinal microvascular endothelial cells as well, which constitute diabetic retinopathy.
- rifamycin SV and 3-formyl rifamycin, derivatives of rifampicin exhibit similar activity potently.
- the present invention would provide angiogenesis inhibitors having potent angiogenesis-inhibiting activity and used for wide range of diseases including angiogenesis in malignant tumor, diabetic retinopathy, retinal angiogenesis and angiogenesis accompanying cardiovascular diseases, respectively. Because rifampicin, the active ingredient of the present invention, has been used as an antibacterialmedicine, its safety has been confirmed and methods for production and administration established, therefore, the angiogenesis inhibitors of the present invention are promising as highly practical angiogenesis inhibitors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
Description
- The present invention relates to an angiogenesis inhibitor rifampicin, and more particularly, to a novel angiogenesis inhibitor rifampicin effective for inhibition of angiogenesis in malignant tumor, diabetic retinopathy, retinal angiogenesis, and angiogenesis accompanying cardiovascular remodeling.
- Angiogenesis is a process in which new blood vessels are generated from existing blood vessels, and it is known that angiogenesis is closely involved in an onset and development of diseases such as malignant (solid) tumor, diabetic retinopathy, or retinal angiogenesis, inflammatory diseases (rheumatism, etc.). For example, in order for solid tumors to grow, it is necessary to secure a supply route of nutrition and oxygen and an elimination route of wastes by angiogenesis. Angiogenesis plays an important role for tumor metastasis, an issue special concern for cancer treatment, since angiogenesis secures the blood supply. As for diabetic retinopathy, angiogenesis itself is a pathological condition, and patients lose their eyesight if left untreated. Therefore, it is considered that inhibition of angiogenesis leads to prevention/treatment of diseases, and preventing/treating agents for angiogenesis are currently explored.
- Since angiogenesis promotes various pathological conditions mentioned above, inhibition of angiogenesis is expected to be beneficial in prevention/treatment of such conditions. For the purpose of prevention or treatment of diseases associated with angiogenesis, studies in search for angiogenesis-inhibiting substances have been performed. As a result, many angiogenesis-inhibiting substances have been identified, and for some of them, clinical usefulness is now under investigation.
- For instance, angiogenesis inhibitors such as endostatin and angiostatin were once known to be the most potent agents for tumor dormancy therapy. They were expected to serve as ideal anticancer drugs with least adverse reactions because their systemic therapy regressed solid tumors in experimental animals remarkably (Cell, 88, 277-285, 1997) without any acquired resistance as experimental tumors do not develop resistance to multiple cycles of therapy unlike conventional anticancer drugs (Nature, 390, 404-407, 4997). However, in clinical practice, synthesis of an effective dosage of these high molecular proteins to elicit antitumor effect is difficult and costly and, consequently, business circles have already abandoned clinical applications of angiostatin, whose molecular weight is about 50000.
- Endostatin, with lower molecular weight (about 20000), attracted attention and its clinical applications have started in terminal malignant tumor patients in U.S.A. However, its precise mechanisms of action as well as its receptors had been unknown.
- Endostatin inhibits the proliferation of endothelial cells and induces apoptosis under reduced serum culture condition (J. Biol. Chem., 274, 11721-11726, 1999), but since the effect was limited, and it was difficult to ascribe the potent effect to regress primary and metastatic cancers. Tumor cells attain accelerated proliferative characteristics not only by genomic mutation and deregulated gene expression but also by vigorously secreting many growth- and angiogenesis-promoting factors in an autocrine/paracrine fashion; and further, newly generated blood vessels supply abundant blood flow. In order for endostatin to inhibit tumor angiogenesis under such circumstances as currently reported, potent intracellular signals specificallyacting on endothelial cells must be induced. These mechanisms have been unknown for long time.
- On the other hand, in 1957, P. Sensi et al. of Lepetit Research Laboratories in Italy separated Streptomyces mediterranei (later, classified into Nocardio mediterranei) from soil collected at the coast of the Mediterranean, and obtained rifamycin, an antibiotic showing antibacterial activity to acid-fast bacteria and Gram-positive bacteria from the culture liquid thereof. Rifamycin in the culture liquid is a mixture comprising rifamycins A, B, C, D, E, etc., and rifamycin O is an oxidized type of rifamycin B. Rifamycin B and rifamycin O are induced into rifamycin S, and rifamycin S is reduced to rifamycin SV by ascorbic acid. 3-formyl rifamycin is made by 3-formylation of rifamycin. Rifampicin is induced from a substance made by 3-formylation of rifamycin SV. Rifamycin is collectively called as ansamycin antibiotics because it has an aromatic ring system to which an aliphatic bridge called ansa ring is connected.
- In addition, the above-mentioned rifampicin is an ansamycin antibiotic developed from a collaboration of Ciba-Geigy (Switzerland) and Lepetit (Italy), and is induced from a substance made by 3-formylation of rifamycin SV. In other words, rifampicin is an ansamycin semisynthetic antibiotic having a structure of 3-{[(4-methyl-1-piperazinyl)imino]methyl}rifamycin, and is a substance which has excellent antituberculosis activity and has been used widely as an anti-tuberculous drug. Rifampicin has antibacterial activity not only to Gram-positive bacteria but also to Gram-negative bacillus, and has been used for brucellosis, chlamydia infection, and infection of Gram-positive bacteria such as staphylococcus as well as tuberculosis.
- Malkowska-Zwierz et al. discloses that rifampicin inhibits the angiogenic activity of human blood mononuclears (MNC) in a leukocyte induced angiogenesis test but not the angiogenic activity of tumour cells in a tumour induced angiogenesis test (MALKOWSKA-ZWIERZ ET AL., INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 7, 1995, page 968).
- Rifampicin is synthesized by reacting 3-formyl rifamycin SV with 1-amino-4-methylpiperazine in tetrahydrofran, and many synthetic methods including industrial synthetic methods are disclosed (Japanese Patent Publication Nos.
42-26800 47-23303 53-39400 57-40155 62-41671 62-41672 62-41673 - The object of the present invention is to provide a novel angiogenesis inhibitor which is safe and highly practical, more particularly, a novel angiogenesis inhibitor which is effective, safe and highly practical for inhibition of angiogenesis in various diseases such as malignant tumor, diabetic retinopathy and retinal angiogenesis.
- As a result of intensive search to attain the objective mentioned above, the present inventors have found that rifampicin, which has excellent antituberculous and antibacterial activity to both Gram-positive and negative bacteria and widely used to treat brucellosis, chlamydia infection, and staphylococcus infection as well as tuberculosis, has excellent angiogenesis-inhibiting activity. This led to the completion of the present invention. It is furthermore disclosed that ansamycin antibiotics such as rifamycin SV or 3-formyl rifamycin have angiogenesis-inhibiting activity as well.
- In the present invention, the finding that ansamycin antibiotics such as rifampicin have excellent angiogenesis-inhibiting activity has its origin in the elucidation of endostatin-induced molecular signals by the present inventors. Recently, the present inventors have found a molecular mechanism involved in inhibition of angiogenesis by endostatin (FASEB Journal. 15, 1044-1053, 2001). Administration of endostatin at concentrations showing tumor regression in experimental animals markedly inhibited various immediately early response genes and apoptosis/cell-cycle/migration-associated genes expressed in cultured vascular endothelial cells under supplementation with serum, growth factors and angiogenesis factors.
- As a result of down-regulation of a variety of gene expression, endostatin causes marginal endothelial cell proliferation, but marked inhibition of endothelial cell migration. The molecular responses, which are potent and wide spectrum of gene down-regulation by endostatin, are designated as "angiogenesis-inhibiting signals" by a present inventor. By quantifying mRNA levels using real-time quantitative PCR, it becomes possible to rapidly identify substances showing potent signals similar to endostatin among many reagents, and to examine whether they exert potent inhibition of endothelial cell migration/proliferation.
- Conventional process of identifying novel angiogenesis-inhibiting factors required repetition of protein purification by extracting and fractionating tumor regressive activity released by tumor themselves from a large amount of body fluid and/or supernatant of cell cultures. The entire process was time-consuming and it took long before gene cloning. Further, it was difficult to synthesize a sufficient dosage of large molecular weight angiogenesis-inhibiting factors, endostatin and angiostatin.
- In the present invention, ansamycin antibiotics such as rifampicin have been found to induce strong angiogenesis-inhibiting activity among many candidate substances. Since ansamycins such as rifampicin have been widely used as antibiotics, their safety is well known and method for producing and administering them have been established. Therefore, it is expected that they can be used as highly practical angiogenesis inhibitors.
- The present invention comprises an angiogenesis inhibitor containing an ansamycin antibiotic or a pharmacologically acceptable derivative thereof as an active ingredient ("1"), the angiogenesis inhibitor according to "1", wherein the ansamycin antibiotic is rifampicin, ("2"), the angiogenesis inhibitor according to "1" or "2", wherein the pharmacologically acceptable derivative is a pharmacologically acceptable salt or a hydrate thereof ("3"), the angiogenesis inhibitor according to any one of "1" to "3", wherein angiogenesis in malignant tumor is inhibited ("4"), the angiogenesis inhibitor according to anyone of "1" to "3", wherein angiogenesis in diabetic retinopathy is inhibited ("5"), the angiogenesis inhibitor according to anyone of "1" to "3", wherein angiogenesis in retinal angiogenesis is inhibited ("6") , and the angiogenesis inhibitor according to any one of "1" to "3", wherein angiogenesis accompanying cardiovascular remodeling is inhibited ("8").
- Any parts of the examples referring to compounds not falling within the scope of the invention as claimed are to be considered to represent comparative data.
-
Fig. 1 is a set of views showing angiogenesis-inhibiting signals induced by addition of various concentrations of rifampicin to adult human dermal microvascular endothelial cells. A: FAK gene, B: PECAM-1 gene, C: integrin-αv gene, D: integrin-β3 gene, E: endothelin-1 gene, F: ETB gene, G: c-myc gene, H: Flt gene. -
Fig. 2 is a view showing proliferation-inhibiting activity of rifampicin to adult human dermal microvascular endothelial cells with the use of modified 72-hour-proliferation assay (under the culture in proliferation medium containing 10% fetal bovine serum). -
Fig. 3 is aview showing the time course of advanced distance of wounding edge after denudement of confluent culture of adult human dermal microvascular endothelial cells. Cell migration is significantly inhibited by the addition of rifampicin to the culture medium. -
Fig. 4 is a view showing the result of examination whether oral intake of rifampicin exhibits tumor growth-inhibiting activity to explanted solid tumors derived from human colon cancer cell line (CW-2) in nude mice. Tumor volume is significantly inhibited by oral intake of rifampicin. -
Fig. 5 is a set of views showing relationship between the changes of plasma α-fetoprotein levels and long-term rifampicin administration in two patients with hepatitis C-related liver cirrhosis combined with pulmonary tuberculosis. -
Fig. 6 is a set of views showing angiogenesis-inhibiting signals induced by various concentrations of rifampicin, rifamycin SV and 3-formyl rifamycin in human retinal microvascular endothelial cells. It is shown that each mRNA amount of c-myc, integrin-αv, integrin-β3 is inhibited in a concentration-dependent manner. - The present invention comprises angiogenesis inhibitors containing the ansamycin antibiotic rifampicin or a pharmacologically acceptable derivative thereof as defined below as an active ingredient. The angiogenesis inhibitor can be used for inhibiting angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis and angiogenesis accompanying cardiovascular remodeling , respectively.
- The active ingredients of the present invention comprise ansamycin antibiotics such as rifampicin. The active ingredients of the present invention can be appropriately converted into, for example, pharmacologically acceptable derivatives in order to increase water-solubility for the purpose of easier administration (Japanese Patent Publication No.
5-44467 - For administration of the angiogenesis inhibitor of the present invention, appropriate administration method such as oral or parenteral administration (intravenous, intramuscular, subcutaneous administration, or instillation) can be used in accordance with subjects of administration. In case of oral administration, the active ingredients of the present invention can be formulated as a solid or liquid prescribed drug, for instance, in the form of tablets, granules, capsules, powders, troches, solutions, suspensions, or emulsions. In case of parenteral administration, the active ingredients of the present invention can be prepared as, for example, an injectable prescribed drug by using an appropriate solvent. Examples of such solvent include water, aqueous solvents (sodium chloride solution, glucose solution, etc.), water-miscible solvents (ethyl alcohol, polyethylene glycol, propylene glycol, etc.), and nonaqueous solvents (corn oil, cottonseed oil, peanut oil, sesame oil, etc.). When applying them to diseases such as diabetic retinopathy, the active ingredients of the present invention can be administered as a formulation of eyedrops.
- Dosage of the active ingredients of the present invention is appropriately determined according to subjects and forms of administration, however, as an example of dosage unit for oral administration, an amount containing about 50 - 1000 mg of the active ingredients, preferably, about 150 - 500 mg of the active ingredients, is exemplified.
- Rifampicin, the active ingredient of the present invention, is a medicine which have been already used for innumerable patients including tuberculosis patients, and its dosage regimen and side effect are well known. Therefore, when using the medicines of the present invention, dosage form and dosage method based on such experiences can be used.
- The present invention will be described more specifically with examples. The technical scope of the present invention is not limited to these but defined by the claims. Any parts of the examples referring to compounds not falling within the scope of the invention as claimed are to be considered to represent comparative data.
- Exponentially growing adult human dermal microvascular endothelial cells in the presence of serum/growth factors/angiogenesis-promoting factors were incubated with various concentrations of rifampicin for four hours, and extracted RNAs were subjected to quantification of mRNA of various genes using LightCycler-based highly sensitive real-time quantitative PCR (FASEB J., 15, 1044-1053, 2001). The results are shown in
Fig. 1 . In the figure, A represents the results of quantification of focal adhesion kinase gene, B represents those of platelet endothelial cell adhesion molecule-1 (PECAM-1) genes, C represents those of integrin-αv gene which is an adhesive factor, D represents those of integrin-β3 gene which is another adhesive factor, E represents those of endothelin-1 gene which is a vasoconstrictive peptide, F represents those of endothelin receptor subtype B (ETB) gene, G represents those of c-myc gene which is an immediate early response gene, and H represents those of Flt gene which is a subtype of vascular endothelial growth factor (VEGF) receptor, respectively. - As shown in
Fig. 1 , addition of various concentrations of rifampicin induced angiogenesis-inhibiting signals showing spectra similar to those of endostatin. - The effect of rifampicin on the proliferation of endothelial cells was examined by modified 72-hour-proliferation assay (Cell, 88, 277-85, 1997).
- Under the culture in growth medium containing 10% fetal bovine serum, various concentrations of rifampicin were added to exponentially growing adult human dermal microvascular endothelial cells for 48 - 72 hours, and the cell number was counted by an automated blood cell counter.
- The results are shown in
Fig. 2 . Rifampicin inhibited the proliferation of adult human dermal microvascular endothelial cells in a concentration-dependent manner. - Inhibitory activity of rifampicin against cell migration was examined by monolayer wounding method (FASEB J., 15, 1044-1053, 2001).
- Confluent culture of adult human dermal microvascular endothelial cells under the culture in growth medium containing 10% fetal bovine serum were pretreated with 40 µg/ml of rifampicin for 24 hours, denuding was conducted by the monolayer wounding method, photomicrographs were taken chronologically and advanced distances of wounding edge were measured.
- The results are shown in
Fig. 3 . The advanced distances of vascular endothelial cells were markedly decreased by the addition of 40 µg/ml of rifampicin. - As shown in
Fig. 3 , rifampicin inhibited chemotactic migration of adult human dermal microvascular endothelial cells. - Whether oral intake of rifampicin shows regression of primary solid tumor/metastatic tumors derived from explanted human colon cancer cell lines (CW-2) in nude mice was examined in accordance with the original method of O'Reilly et al. (Cell, 79, 315-28, 1994; Cell, 88, 277-85, 1997). The results are shown in
Fig. 4 . - As shown in
Fig. 4 , oral intake of rifampicin starting when the size of solid tumors reached 200 mm3 significantly inhibited tumor growth in comparison with a group which did not receive rifampicin. - The present inventor specializing in liver diseases administered rifampicin to patients with hepatitis C-related liver cirrhosis associated with lung tuberculosis, and noted a rapid drop in plasma α-fetoprotein levels. The present inventors further noted that hepatoma never recurred during the long term despite the repeated previous episodes of recurrence. Relationship between the changes of plasma α-fetoprotein levels and rifampicin administration in two patients is shown in
Fig. 5 . - Human retinal microvascular endothelial cells were rendered to grow exponentially in the presence of serum/growth factors/angiogenesis-promoting factors, and various concentrations of rifampicin, rifamycin SV and 3-formyl rifamycin were added. After four hours-incubation, RNA was extracted and subjected to mRNA quantification of various genes using aforementioned LightCycler-based highly sensitive real-time quantitative PCR. The results are shown in
Fig. 6 . A, B and C represent the quantification results of c-myc gene; D, E and F represent those of integrin-αv gene; G, H and I represent those of integrin-β3 gene. Further, A, D and G indicate the changes of mRNA levels after adding rifampicin; B, E and H indicate those after adding rifamycin SV; C, F and I indicate those after adding 3-formyl rifamycin. As shown inFig. 6 , angiogenesis-inhibiting signals are markedly elicited by rifampicin in human retinal microvascular endothelial cells as well, which constitute diabetic retinopathy. Simultaneously, it is revealed that both rifamycin SV and 3-formyl rifamycin, derivatives of rifampicin, exhibit similar activity potently. - The present invention would provide angiogenesis inhibitors having potent angiogenesis-inhibiting activity and used for wide range of diseases including angiogenesis in malignant tumor, diabetic retinopathy, retinal angiogenesis and angiogenesis accompanying cardiovascular diseases, respectively. Because rifampicin, the active ingredient of the present invention, has been used as an antibacterialmedicine, its safety has been confirmed and methods for production and administration established, therefore, the angiogenesis inhibitors of the present invention are promising as highly practical angiogenesis inhibitors.
Claims (2)
- Use of rifampicin, a pharmacologically acceptable salt or a hydrate thereof for the manufacture of a medicament for inhibiting angiogenesis, wherein the angiogenesis is selected from angiogenesis in malignant tumor, angiogenesis in diabetic retinopathy, angiogenesis in retinal angiogenesis, and angiogenesis accompanying cardiovascular remodeling.
- Use according to claim 1 for inhibiting angiogenesis in malignant tumor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08168507A EP2016944A3 (en) | 2002-06-21 | 2003-06-19 | Angiogenesis inhibitor containing a derivative of rifampicin |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002181281 | 2002-06-21 | ||
JP2002181281 | 2002-06-21 | ||
JP2003118960 | 2003-04-23 | ||
JP2003118960A JP4393098B2 (en) | 2002-06-21 | 2003-04-23 | New uses of ansamycin antibiotics and screening methods for new angiogenesis inhibitors |
PCT/JP2003/007813 WO2004000307A1 (en) | 2002-06-21 | 2003-06-19 | Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08168507A Division EP2016944A3 (en) | 2002-06-21 | 2003-06-19 | Angiogenesis inhibitor containing a derivative of rifampicin |
EP08167827 Division | 2008-10-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1516620A1 EP1516620A1 (en) | 2005-03-23 |
EP1516620A4 EP1516620A4 (en) | 2005-09-07 |
EP1516620B1 true EP1516620B1 (en) | 2009-01-14 |
Family
ID=30002254
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08168507A Withdrawn EP2016944A3 (en) | 2002-06-21 | 2003-06-19 | Angiogenesis inhibitor containing a derivative of rifampicin |
EP03733506A Expired - Lifetime EP1516620B1 (en) | 2002-06-21 | 2003-06-19 | Rifampicin for treating angiogenesis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08168507A Withdrawn EP2016944A3 (en) | 2002-06-21 | 2003-06-19 | Angiogenesis inhibitor containing a derivative of rifampicin |
Country Status (6)
Country | Link |
---|---|
US (2) | US20060035878A1 (en) |
EP (2) | EP2016944A3 (en) |
JP (1) | JP4393098B2 (en) |
KR (2) | KR20070008719A (en) |
DE (1) | DE60325855D1 (en) |
WO (1) | WO2004000307A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008001720A (en) * | 2002-06-21 | 2008-01-10 | Japan Science & Technology Agency | Novel use of ansamycin antibiotic and method of screening novel angiogenesis inhibitor |
ITMI20041295A1 (en) * | 2004-06-25 | 2004-09-25 | Cosmo Spa | ORAL ANTI-MICROBIAL PHARMACEUTICAL COMPOSITIONS |
WO2007077893A1 (en) * | 2006-01-04 | 2007-07-12 | National University Corporation, Tokyo Medical And Dental University | Therapeutic agent for liver disease and hepatic function-ameliorating agent |
WO2007148714A1 (en) * | 2006-06-21 | 2007-12-27 | Kaneka Corporation | Implant using rifamycin derivative |
WO2007148713A1 (en) * | 2006-06-21 | 2007-12-27 | Kaneka Corporation | Drug for treating vascular disease or drug for controlling cell proliferation comprising rifamycin derivative as the active ingredient |
JP2010111582A (en) * | 2007-02-15 | 2010-05-20 | Tokyo Medical & Dental Univ | Therapeutic agent for liver cancer comprising rifampicin as component |
EP2333546A4 (en) * | 2008-08-28 | 2011-12-21 | Nat Univ Corp Tokyo Med & Dent | Method for screening for antiangiogenic agent, and method for screening for antiangiogenic signal gene |
US20170202850A1 (en) * | 2014-07-21 | 2017-07-20 | Hiroaki Serizawa | Ophthalmic compositions of rifamycins and uses thereof |
JP7187310B2 (en) * | 2015-10-08 | 2022-12-12 | エーエムディー セラピューティックス エルエルシー | Treatment of skin disorders by topical administration of VEGF inhibitors |
KR102613900B1 (en) * | 2015-11-13 | 2023-12-15 | 서울대학교 산학협력단 | Transgenic pigs expressing both TNFRI-Fc and HO-1 without Gal epitope and the use of thereof |
KR101916801B1 (en) * | 2016-08-12 | 2018-11-08 | 경북대학교 산학협력단 | A drug screening method for diseases associated choroidal neovascularization using biomimetic three dimensional in vitro system |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5339400A (en) | 1976-09-22 | 1978-04-11 | Iwanouitsuchi Ponomar Arekusei | |
JPS5740155A (en) | 1980-08-19 | 1982-03-05 | Ishikawajima Harima Heavy Ind Co Ltd | Overload safety device |
JPS6241673A (en) | 1985-08-14 | 1987-02-23 | ハワ−ド エ− サツセ | Golf club |
JPS6241671A (en) | 1985-08-15 | 1987-02-23 | コスモ石油株式会社 | Gas blocking apparatus |
JPS6241672A (en) | 1985-08-15 | 1987-02-23 | 日本ドライケミカル株式会社 | Window glass crusher |
GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
ATE130517T1 (en) * | 1990-08-08 | 1995-12-15 | Takeda Chemical Industries Ltd | INTRAVASCULAR EMBOLIZING AGENT CONTAINING A SUBSTANCE INHIBITING ANGIOGENESIS. |
JPH0544467A (en) | 1991-08-19 | 1993-02-23 | Nippondenso Co Ltd | Water pump for engine |
US6406880B1 (en) * | 1997-05-02 | 2002-06-18 | Integrated Research Technology, Llc | Betaines as adjuvants to susceptibility testing and antimicrobial therapy |
CA2331620A1 (en) * | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
MXPA02001439A (en) * | 1999-08-11 | 2002-08-30 | Eos Biotechnology Inc | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators. |
-
2003
- 2003-04-23 JP JP2003118960A patent/JP4393098B2/en not_active Expired - Fee Related
- 2003-06-19 KR KR1020067025459A patent/KR20070008719A/en active Search and Examination
- 2003-06-19 WO PCT/JP2003/007813 patent/WO2004000307A1/en active Application Filing
- 2003-06-19 US US10/518,870 patent/US20060035878A1/en not_active Abandoned
- 2003-06-19 KR KR1020047019629A patent/KR100678494B1/en active IP Right Grant
- 2003-06-19 DE DE60325855T patent/DE60325855D1/en not_active Expired - Lifetime
- 2003-06-19 EP EP08168507A patent/EP2016944A3/en not_active Withdrawn
- 2003-06-19 EP EP03733506A patent/EP1516620B1/en not_active Expired - Lifetime
-
2009
- 2009-07-17 US US12/504,823 patent/US9333194B2/en active Active
Non-Patent Citations (2)
Title |
---|
YASUDA M. ET AL: "A novel effect of polymorphonuclear leukocytes in the facilitation of angiogenesis.", LIFE SCIENCES, vol. 66, no. 21, 2000, pages 2113 - 2121 * |
YASUDA M. ET AL: "Differential roles of ICAM-1 and E-selectin in polymorphonuclear leukocyte-induced angiogenesis.", AM J PHYSIOL CELL PHYSIOL, vol. 282, 1 April 2002 (2002-04-01), pages C917 - C925 * |
Also Published As
Publication number | Publication date |
---|---|
EP2016944A2 (en) | 2009-01-21 |
EP2016944A3 (en) | 2009-12-02 |
KR20050008773A (en) | 2005-01-21 |
JP4393098B2 (en) | 2010-01-06 |
EP1516620A4 (en) | 2005-09-07 |
KR100678494B1 (en) | 2007-02-06 |
US20060035878A1 (en) | 2006-02-16 |
KR20070008719A (en) | 2007-01-17 |
EP1516620A1 (en) | 2005-03-23 |
WO2004000307A1 (en) | 2003-12-31 |
US20100004327A1 (en) | 2010-01-07 |
DE60325855D1 (en) | 2009-03-05 |
JP2004075665A (en) | 2004-03-11 |
US9333194B2 (en) | 2016-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9333194B2 (en) | Use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor | |
AU2016299614B2 (en) | Agent for treating and/or preventing adult T cell leukemia/lymphoma | |
CN103347520A (en) | Inhibitor of late SV40 factor (LSF) as cancer chemotherapeutics | |
He et al. | The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer | |
CA3095156A1 (en) | Methods of treating minimal residual cancer | |
CN112656795A (en) | Action mechanism and application of fangchinoline in resisting tuberculosis membrane melanoma | |
JP2002520415A (en) | Anhydrous modified cansalidin analogues useful for the treatment of cancer | |
Gao et al. | Oral administration of indole substituted dipyrido [2, 3-d] pyrimidine derivative exhibits anti-tumor activity via inhibiting AKT and ERK1/2 on hepatocellular carcinoma | |
Huang et al. | One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment | |
Awasthi et al. | Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma | |
WO2021178663A1 (en) | Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors | |
CN114685521A (en) | Alkaloid compound with function of inhibiting PD-1/PD-L1 interaction and application thereof | |
CN109106715B (en) | Application of 8-hydroxyquinoline medicine or salt thereof in preparing medicine for treating BRD4 related diseases | |
CN115990158A (en) | Application of brucea javanica kul as PD-L1 inhibitor | |
Zhang et al. | The eEF1A Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies | |
CN114805117A (en) | Alkannin and alkannin oxime derivatives for anti-tumor stem cells | |
US11534448B2 (en) | Use of canagliflozin in preparation of antitumor drug | |
CN111875606B (en) | Purine compound obtained based on virtual docking and preparation method and application thereof | |
Zhao et al. | CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma | |
CN113876771B (en) | Small molecule drug targeting PABPC1 and application thereof in chronic myelogenous leukemia | |
JP2008001720A (en) | Novel use of ansamycin antibiotic and method of screening novel angiogenesis inhibitor | |
CN112336867A (en) | Composition of PKD inhibitor and anticancer drug and application thereof | |
CN118806769A (en) | Application of mechanical signal perception related YAP (yaP pathway) modulator in preparation of anti-hepadnavirus drugs | |
CN114796503A (en) | Application of KDM6A inhibitor and tyrosine kinase inhibitor in combination in preparation of anti-tumor drugs | |
CN118416226A (en) | Treatment strategy of KU complex inhibitor in targeted tumor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041216 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050727 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/496 B Ipc: 7A 61P 29/00 B Ipc: 7G 01N 33/50 B Ipc: 7A 61K 31/395 A Ipc: 7A 61P 3/10 B Ipc: 7A 61P 35/00 B Ipc: 7C 07D 498/18 B Ipc: 7A 61P 27/02 B Ipc: 7A 61P 9/00 B Ipc: 7G 01N 33/15 B Ipc: 7A 61P 43/00 B |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20060529 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: RIFAMPICIN FOR TREATING ANGIOGENESIS |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR GB IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60325855 Country of ref document: DE Date of ref document: 20090305 Kind code of ref document: P |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20091015 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20210504 Year of fee payment: 19 Ref country code: FR Payment date: 20210506 Year of fee payment: 19 Ref country code: IT Payment date: 20210609 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20210506 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60325855 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20220619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220619 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220619 |